MetaVia Inc (MTVA)

• Market cap: $17.8M
• 1 day: -5.51%
• 5 days: -7.88%
• 1 month: -7.1%
• 3 months: -29.17%
• 6 months: -1.15%
• Year to date: -19.25%
• 1 year: -65.08%
• 5 years: -99.95%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Employees: 8